SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
---------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 16, 2006
LIGAND PHARMACEUTICALS INCORPORATED
(Exact name of registrant as specified in its charter)
DELAWARE
(State or other jurisdiction of incorporation)
000-20720
(Commission File Number)
10275 Science Center Drive,
San Diego, California
(Address of principal executive offices)
(858) 550-7500
(Registrant's telephone number, including area code)
77-0160744
(I.R.S. Employer Identification No.)
92121-1117
(Zip Code)
Item 2.02 Disclosure of Results of Operations and Financial Condition
On March 16, 2006, the registrant reported its financial results for its
fourth quarter and year ended December 31, 2005. A copy of the press release
issued by the registrant on March 16, 2006 concerning the foregoing results is
furnished herewith as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01 Financial Statements And Exhibits
(d) Exhibits
Exhibit No. Description
99.1 Press Release of the Company dated March 16, 2006
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has caused this report to be signed on its behalf by the
undersigned.
LIGAND PHARMACEUTICALS INCORPORATED
Date : March 16, 2006 By: /s/ Warner R. Broaddus
Name: Warner Broaddus
Title: Vice President, General Counsel & Secretary